ZAMFIROVA v. AMAG PHARMACEUTICALS, INC.
Case Number:
2:20-cv-00152
Court:
Nature of Suit:
Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
May 08, 2025
AMAG Inks $7.5M Deal In Suit Over Preterm-Birth Drug
AMAG Pharmaceuticals has agreed to pay $7.5 million to resolve a group of women's proposed class action accusing it of misleading consumers into believing one of its drugs reduced the risk of preterm births, according to a motion filed Thursday seeking a New Jersey federal court's preliminary approval of the deal.
-
May 25, 2021
AMAG Escapes Suit Over Preterm Birth Drug's Effectiveness
A New Jersey federal judge on Tuesday threw out a suit alleging that AMAG Pharmaceuticals Inc. misleads consumers into believing one of its drugs prevents women from giving birth prematurely, saying any claims from before March 2019 are preempted.
-
October 26, 2020
Feds Float Drop Of Preterm Birth Drug Approval, Women Say
A group of women challenging AMAG Inc.'s marketing and sale of a drug advertised as reducing the chance of preterm births has told a New Jersey federal court that a U.S. Food and Drug Administration division has proposed to withdraw market approval of the drug.聽